Is it feasible to go to Georgia for IVF with chromosomal abnormalities? Real conditions and process analysis

IVF in Georgia for Chromosomal Abnormalities: A Misconception That Needs to Be Addressed First

Many carriers of chromosomal abnormalities or their family members, upon hearing the term "chromosomal problem," immediately think, "I can never have a healthy child of my own." This is actually a cognitive bias that frequently appears in reproductive clinics. Chromosomal abnormalities do increase the risk of miscarriage and chromosomal disorders in offspring during natural pregnancy, but modern assisted reproductive technologies—especially preimplantation genetic testing (PGT)—provide a clear solution for this group.

The reason Georgia attracts some patients is straightforward: its laws explicitly allow PGT screening of embryos (including PGT-SR for structural abnormalities and PGT-A for numerical abnormalities) and are open to commercial surrogacy for married couples. However, this does not mean that "anyone with a chromosomal abnormality can succeed in Georgia." Below, we break down the feasibility conditions, process, and risks based on real decision-making logic.

Direct Answer: When is it Suitable and When is it Not?

Suitable for IVF in Georgia (all conditions must be met):

• A clear type of chromosomal abnormality that can be screened by PGT-SR or PGT-A has been identified through genetic counseling, such as balanced translocation, Robertsonian translocation, inversion, marker chromosomes, aneuploidy (e.g., Klinefelter syndrome, Turner syndrome), and some high-incidence microdeletions/duplications (combined with microarray technology).
• At least one partner has retrievable mature eggs and sperm, capable of forming a biopsiable blastocyst.
• The financial capacity to bear the total cost of the overseas cycle (usually 40%–100% higher than domestic costs).
• Acceptance of embryo biopsy and frozen cycles, and no ethical objections to genetic material testing.

Unsuitable or cautionary cases:

• Special genetic issues that cannot be resolved by PGT alone, such as mitochondrial diseases or certain monogenic disorders combined with extrachromosomal mutations.
• Severely diminished ovarian reserve (AMH < 0.5 ng/mL, antral follicle count < 3) and unwillingness to accept egg donation.
• Male azoospermia where sperm cannot be obtained via testicular aspiration (even with chromosomal abnormalities, no usable embryos).
• Significant concerns about Georgia's laws regarding embryo disposition, rights of the gestational carrier, etc.
• Uncontrolled systemic diseases (e.g., severe diabetes, hypertension, autoimmune diseases) that require treatment first.

Why Do Chromosomal Abnormalities Occur? A Doctor's Perspective

Classification of Causes

The core logic for reproductive medicine doctors handling such cases is: first distinguish whether the patient is a "chromosomal carrier" or a "high producer of aneuploid gametes (sperm/eggs)." The former (e.g., balanced translocation) requires PGT-SR to select embryos carrying or not carrying the translocation; the latter (e.g., recurrent miscarriage in women over 38) relies on PGT-A to screen for euploid embryos. Reproductive centers in Georgia have both capabilities, but differences exist among centers in biopsy timing (Day 5 or Day 6 blastocyst), testing platforms (NGS or aCGH), and reporting time, which patients should proactively confirm during consultation.

Common Pitfalls: Legal Boundaries and Technical Limitations

Pitfall 1: Assuming "PGT-passed embryos are 100% healthy." Both PGT-A and PGT-SR can only detect chromosomal numerical abnormalities and large structural abnormalities (typically with a resolution of 5-10 Mb). They cannot rule out monogenic diseases, microdeletions/duplications (e.g., 22q11.2 microdeletion), or abnormalities with mosaicism below 30%. Doctors usually recommend combining with prenatal diagnosis (amniocentesis) for final confirmation, but many overseas patients skip this step due to distance, which is a risk to be aware of.

Pitfall 2: Georgia's laws have gray areas regarding the scope of "embryo genetic diagnosis." While the law allows PGT to prevent serious genetic diseases, it explicitly prohibits "non-medical sex selection" or "specific gene screening (e.g., for height or intelligence)." Some intermediaries may promote vague information, and in practice, embryos may be rejected for testing or reports delayed. Reputable centers require genetic counseling records and disease diagnosis certificates.

Pitfall 3: Ignoring the impact of embryo biopsy on blastocyst quality. Biopsy removes 5-10 trophectoderm cells, which may reduce implantation rates for morphologically poor blastocysts (e.g., grade C expanded blastocysts). Doctors advise against biopsying low-quality blastocysts, but patients often insist on biopsy to "ensure chromosomal normality," ultimately leading to no usable embryos. It is recommended to decide on biopsy based on embryo development after egg retrieval, rather than setting a fixed plan in advance.

Actual Process: Timeline from Genetic Counseling to Transfer

Using Georgia as an example, a complete cycle typically includes the following steps (excluding preliminary examinations):

1. Domestic phase (1-2 months): Complete basic fertility assessment (AMH, sex hormone panel, ultrasound antral follicle count), semen analysis, blood type and infection screening, chromosomal karyotype analysis (both partners), genetic counseling, and obtain written reports. Some centers require previous miscarriage tissue chromosomal analysis results.
2. Initial overseas consultation (optional, can be remote): Confirm the plan via video consultation, sign informed consent (including PGT intent, embryo disposition, fate of remaining embryos, etc.).
3. Ovarian stimulation and egg retrieval (approximately 2-week stay in Georgia): Start stimulation on day 2-3 of the menstrual cycle, average medication for 10-12 days, egg retrieval under general anesthesia.
4. Blastocyst culture and biopsy (5-7 days after egg retrieval): The laboratory performs trophectoderm biopsy on usable blastocysts (typically requiring ≥3BC grade), then sends cells to a partner genetic laboratory (some centers have in-house labs, report time 3-5 weeks).
5. Embryo freezing and PGT waiting period: Biopsied blastocysts are vitrified and frozen while awaiting genetic reports.
6. Report interpretation and embryo selection: The doctor selects "euploid" or "balanced carrier" embryos based on the report and explains possible mosaicism or uncertainties to the patient.
7. Endometrial preparation and transfer (optional frozen embryo cycle, requires another 10-14 day stay in Georgia): Prepare the endometrium using a hormone replacement cycle and schedule the transfer.

The entire process from the first trip to Georgia to the end of transfer usually takes 3-5 months. If multiple egg retrievals or third-party assisted reproduction (surrogacy) are involved, the time extends to 6-12 months.

Frequently Asked Questions: Four Key Concerns

• Q: For balanced translocation, what is the success rate of IVF in Georgia?
  A: The success rate mainly depends on the woman's age and ovarian response. For women under 35, the probability of obtaining 3 or more biopsiable blastocysts is about 60%-70%, of which approximately 30%-50% of embryos may be euploid or balanced carriers (depending on the translocation breakpoints). The live birth rate per transferred euploid embryo is about 40%-55%, similar to patients of the same age without chromosomal abnormalities. Success rates decrease by about 15-20% for every 5-year increase in age.
• Q: Are Georgia's legal restrictions on PGT strict?
  A: Currently, Georgian law allows PGT for "prevention of genetic diseases" but does not allow direct sex selection or eugenic screening for non-medical purposes. In practice, as long as medical indications confirmed by genetic counseling are provided (e.g., recurrent miscarriage, known chromosomal abnormality carrier, advanced age), overseas patients can proceed smoothly. It is recommended to choose an embryo laboratory with JCI or ESHRE certification to avoid unqualified clinics.
• Q: What if all embryos have chromosomal abnormalities?
  A: This is the most disappointing but unavoidable scenario. Possible reasons include: a high proportion of aneuploidy in the eggs or sperm themselves (e.g., premature ovarian failure or high sperm chromosome breakage rate), abnormal embryo development leading to biopsy failure, or laboratory testing errors. In such cases, consider egg/sperm donation (Georgia allows egg donation through正规 egg banks) or adjust the stimulation protocol for another attempt.
• Q: How do local hospitals in Georgia protect patient rights?
  A: Reputable reproductive centers require signing a detailed treatment agreement, including a cost breakdown, embryo ownership, disposal of remaining embryos (donation for research or destruction), and whether a refund is provided if treatment fails. It is advisable for patients to verify the legality of contract terms through a local lawyer or the embassy in China to avoid misunderstandings due to language barriers.

Practitioner's Insight: Rational Advice from a Doctor's Perspective

As a reproductive medicine doctor who has long dealt with patients with chromosomal abnormalities, I have seen too many patients fly overseas with the obsession of "must have a healthy embryo," ignoring three prerequisites: ovarian age, sperm quality, and the severity of the abnormality type itself. Georgia's technical support (NGS platforms, skilled embryology teams, frozen blastocyst bank management) is among the top tier in CIS countries, but it still cannot defy the natural laws of biology. A 46-year-old woman with an AMH of only 0.3 would struggle to obtain a transferable embryo even with normal chromosomes, let alone with chromosomal abnormalities.

Another often overlooked detail is: genetic counseling for chromosomal abnormalities must be conducted by a doctor with a background in reproductive genetics, not a general obstetrician. Many patients simply have a karyotype analysis done domestically and conclude they "can or cannot," but for high-incidence breakpoint translocations (e.g., t(4;8)(p16;q21)), it is necessary to calculate the theoretical proportion of normal embryos and compare it with the detection range of PGT-SR. If the breakpoint is in an area difficult to cover by FOI (fragment overlap identification) detection, other countries (e.g., those using more comprehensive preimplantation genetic testing platforms) should be considered first.

Risk Reminder

Finally, it must be emphasized: Any overseas assisted reproduction carries non-negligible risks. These include but are not limited to:

• Damage to embryos during transport and cryopreservation (especially increased fragility after biopsy);
• Delays in plan adjustments due to poor communication with the local medical team;
• Possible changes in Georgian laws in the near future (e.g., surrogacy restrictions), requiring attention to policy updates;
• Financially, if one cycle fails, the cumulative cost of a second stimulation could reach $100,000-$150,000.

It is recommended that all patients considering this path first complete a full genetic counseling and fertility assessment domestically. Then, based on actual data (age, AMH, sperm DNA fragmentation index, chromosomal karyotype), conduct video consultations with at least two overseas centers to compare plan details before making a decision. Do not be swayed by "success stories," and do not underestimate the limitations imposed by your own condition. True hope is built on objective data and rational planning.